1
|
Sallinen H, Janhonen S, Pölönen P, Niskanen H, Liu OH, Kivelä A, Hartikainen JM, Anttila M, Heinäniemi M, Ylä-Herttuala S, Kaikkonen MU. Comparative transcriptome analysis of matched primary and distant metastatic ovarian carcinoma. BMC Cancer 2019; 19:1121. [PMID: 31744494 PMCID: PMC6862850 DOI: 10.1186/s12885-019-6339-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2019] [Accepted: 11/06/2019] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND High grade serous ovarian carcinoma (HGSOC) is the most common subtype of epithelial ovarian cancers (EOC) with poor prognosis. In most cases EOC is widely disseminated at the time of diagnosis. Despite the optimal cytoreductive surgery and chemotherapy most patients develop chemoresistance, and the 5-year overall survival being only 25-35%. METHODS Here we analyzed the gene expression profiles of 10 primary HGSOC tumors and 10 related omental metastases using RNA sequencing and identified 100 differentially expressed genes. RESULTS The differentially expressed genes were associated with decreased embryogenesis and vasculogenesis and increased cellular proliferation and organismal death. Top upstream regulators responsible for this gene signature were NR5A1, GATA4, FOXL2, TP53 and BMP7. A subset of these genes were highly expressed in the ovarian cancer among the cancer transcriptomes of The Cancer Genome Atlas. Importantly, the metastatic gene signature was suggestive of poor survival in TCGA data based on gene enrichment analysis. CONCLUSION By comparing the gene expression profiles of primary HGSOC tumors and their matched metastasis, we provide evidence that a signature of 100 genes is able to separate these two sample types and potentially predict patient survival. Our study identifies functional categories of genes and transcription factors that could play important roles in promoting metastases and serve as markers for cancer prognosis.
Collapse
Affiliation(s)
- H. Sallinen
- Department of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland
| | - S. Janhonen
- Department of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland
- Institute of Clinical Medicine, School of Medicine, University of Eastern Finland, Kuopio, Finland
| | - P. Pölönen
- Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland
| | - H. Niskanen
- A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland
| | - O. H. Liu
- A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland
| | - A. Kivelä
- A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland
| | - J. M. Hartikainen
- Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland
| | - M. Anttila
- Department of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland
| | - M. Heinäniemi
- Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland
| | - S. Ylä-Herttuala
- A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland
| | - M. U. Kaikkonen
- A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland
| |
Collapse
|
2
|
Kuusanmäki H, Dufva O, Leppä AM, Pölönen P, Heinäniemi M, Porkka K, Kontro M, Heckman C, Mustjoki S. PS973 BCL-XL AS A PUTATIVE THERAPY TARGET IN ACUTE ERYTHROID LEUKEMIA. Hemasphere 2019. [DOI: 10.1097/01.hs9.0000562196.89852.c2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
3
|
Laukkanen S, Grönroos T, Pölönen P, Kuusanmäki H, Mehtonen J, Cloos J, Ossenkoppele G, Gjertsen B, Øystein B, Heckman C, Heinäniemi M, Kontro M, Lohi O. In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL. Blood Cancer J 2017; 7:e604. [PMID: 28885610 PMCID: PMC5709756 DOI: 10.1038/bcj.2017.87] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Affiliation(s)
- S Laukkanen
- Tampere Center for Child Health Research, University of Tampere, and Tampere University Hospital, Tampere, Finland
| | - T Grönroos
- Tampere Center for Child Health Research, University of Tampere, and Tampere University Hospital, Tampere, Finland
| | - P Pölönen
- Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland
| | - H Kuusanmäki
- Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
| | - J Mehtonen
- Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland
| | - J Cloos
- Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands
| | - G Ossenkoppele
- Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
| | - B Gjertsen
- Department of Clinical Science, Hematology Section, University of Bergen, Bergen, Norway.,Department of Internal Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway
| | - B Øystein
- Department of Clinical Science, Hematology Section, University of Bergen, Bergen, Norway.,Department of Internal Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway
| | - C Heckman
- Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
| | - M Heinäniemi
- Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland
| | - M Kontro
- Department of Hematology, Hematology Research Unit Helsinki, University of Helsinki, and Helsinki University Central Hospital Cancer Center, Helsinki, Finland
| | - O Lohi
- Tampere Center for Child Health Research, University of Tampere, and Tampere University Hospital, Tampere, Finland
| |
Collapse
|
4
|
Liuksiala T, Teittinen KJ, Granberg K, Heinäniemi M, Annala M, Mäki M, Nykter M, Lohi O. Overexpression of SNORD114-3 marks acute promyelocytic leukemia. Leukemia 2013; 28:233-6. [PMID: 23979522 DOI: 10.1038/leu.2013.250] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- T Liuksiala
- 1] Institute of Biomedical Technology, University of Tampere, Tampere, Finland [2] Department of Signal Processing, Tampere University of Technology, Tampere, Finland
| | - K J Teittinen
- Tampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Tampere, Finland
| | - K Granberg
- 1] Institute of Biomedical Technology, University of Tampere, Tampere, Finland [2] Department of Signal Processing, Tampere University of Technology, Tampere, Finland
| | - M Heinäniemi
- A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - M Annala
- 1] Institute of Biomedical Technology, University of Tampere, Tampere, Finland [2] Department of Signal Processing, Tampere University of Technology, Tampere, Finland
| | - M Mäki
- Tampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Tampere, Finland
| | - M Nykter
- 1] Institute of Biomedical Technology, University of Tampere, Tampere, Finland [2] BioMediTech, Tampere, Finland
| | - O Lohi
- Tampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Tampere, Finland
| |
Collapse
|
5
|
Pendás-Franco N, García JM, Peña C, Valle N, Pálmer HG, Heinäniemi M, Carlberg C, Jiménez B, Bonilla F, Muñoz A, González-Sancho JM. DICKKOPF-4 is induced by TCF/beta-catenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogenesis and is repressed by 1alpha,25-dihydroxyvitamin D3. Oncogene 2008; 27:4467-77. [PMID: 18408752 DOI: 10.1038/onc.2008.88] [Citation(s) in RCA: 136] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Aberrant activation of the Wnt/beta-catenin signaling pathway is a hallmark of colon cancer. We show that the Wnt antagonist DICKKOPF-4 (DKK-4) gene is repressed by 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) in human colon cancer cells. This effect correlated with the inhibition of the DKK-4 promoter. Chromatin immunoprecipitation assays revealed that 1,25(OH)2D3 induces early and transient binding of the vitamin D receptor (VDR) and the SMRT corepressor to the region adjacent to the transcription start site of DKK-4. Additionally, we demonstrate that the DKK-4 gene is a new downstream target of TCF/beta-catenin. Remarkably, expression of DKK-4 messenger RNA (mRNA) was not detected in a series of 29 human normal (N) colon biopsies but expression was upregulated in all the matched tumour (T) tissues. An inverse correlation existed between the expression of DKK-4 and VDR RNA in the Ts. Ectopic DKK-4 expression increased the migration and invasion properties of colon cancer cells and conditioned media (CM) from DKK-4-expressing cells enhanced the capacity to migrate and form capillary-like tubules of human primary microvascular endothelial cells. In conclusion, DKK-4 is upregulated in colon cancer and is associated with the acquisition of malignant properties by neoplastic cells. DKK-4 downregulation is a novel effect of 1,25(OH)2D3 that may contribute to its anticancer action.
Collapse
Affiliation(s)
- N Pendás-Franco
- Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|